CD177 and cancer: (2011) used a novel cell‐targeting, pH‐sensitive polymeric carrier for the delivery of the anticancer drug bortezomib (BTZ) to cancer cells and found that BTZ was easily conjugated to catechol‐containing polymeric carriers designed to be selectively taken up by cancer cells via cell surface receptor‐mediated mechanisms.